Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 21, 2026.

Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia

Francesco Paonessa, Lewis D. Evans, Ravi Solanki and 5 more

Cell Reports · 2019 · CC BY

doi:10.1016/j.celrep.2018.12.085

Abstract

The neuronal microtubule-associated protein tau, MAPT, is central to the pathogenesis of many dementias. Autosomal-dominant mutations in MAPT cause inherited frontotemporal dementia (FTD), but the underlying pathogenic mechanisms are unclear. Using human stem cell models of FTD due to MAPT mutations, we find that tau becomes hyperphosphorylated and mislocalizes to cell bodies and dendrites in cortical neurons, recapitulating a key early event in FTD. Mislocalized tau in the cell body leads to abnormal microtubule movements in FTD-MAPT neurons that grossly deform the nuclear membrane. This results in defective nucleocytoplasmic transport, which is corrected by microtubule depolymerization. Neurons in the post-mortem human FTD-MAPT cortex have a high incidence of nuclear invaginations, indicating that tau-mediated nuclear membrane dysfunction is an important pathogenic process in FTD. Defects in nucleocytoplasmic transport in FTD point to important commonalities in the pathogenic mechanisms of tau-mediated dementias and ALS-FTD due to TDP-43 and C9orf72 mutations.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The microtubule-associated protein tau (MAPT; tau) is involved in the pathogenesis of several different forms of dementia, including Alzheimer’s disease (AD), progressive supranuclear palsy, Pick’s disease, corticobasal degeneration, and frontotemporal dementia (FTD). FTD is the third most common cause of dementia, after AD and vascular dementia. Autosomal-dominant missense and splicing mutations in MAPT are causes of inherited or familial FTD (FTD-MAPT). However, although it is well established that these mutations lead to hyperphosphorylation and aggregation of tau protein in vivo, the cell biology of neuronal dysfunction and progressive neurodegeneration in this condition are currently not fully understood.

In healthy neurons, tau protein is almost exclusively localized to the axon, and several mechanisms have been suggested for its highly polarized cellular localization, including selective mRNA and protein transport, local translation, and local degradation. Mislocalization and aggregation of tau in neuronal cell bodies are common features of tau-mediated dementias, including FTD and AD. Protein aggregation is widely considered as inherently pathogenic in neurodegeneration, altering many cellular functions, most notably autophagy and proteostasis. However, how MAPT mutations lead to tau hyperphosphorylation and mislocalization, the effects of this mislocalization on neuronal cell biology, and how this contributes to neuronal dysfunction and neurodegeneration all remain poorly understood.

As a typical microtubule-binding protein, tau has several roles in regulating microtubule function and intracellular transport. Tau binds both alpha and beta tubulin subunits of microtubules and has been demonstrated to both stabilize and promote microtubule growth. The presence of tau on microtubules can alter directions and rates of axonal transport. Tau is a natively disordered protein and has recently been found to undergo fluid phase transitions at higher concentrations, nucleating microtubules when it does so. Therefore, it is likely that the changes in tau levels, post-translational modifications, and cellular localization that occur in dementia lead to alterations in microtubule biology, particularly in the neuronal cell body.

To address the question of how MAPT mutations lead to neuronal dysfunction and neurodegeneration, we investigated the effects of two different classes of MAPT mutations on the cell biology of human iPSC-derived cortical neurons. We find that both missense and splicing MAPT mutations cause mislocalization of tau to the cell bodies of neurons and marked changes in microtubule dynamics. Microtubules in the cell bodies of FTD-MAPT neurons actively deform the nuclear membrane, disrupting nucleocytoplasmic transport. Defects in nuclear envelope function, including nucleocytoplasmic transport, are an important pathological process in ALS-FTD because of repeat expansions in C9orf72 and TDP-43 mutations. Our findings demonstrate that dysfunction of the nuclear membrane due to altered microtubule dynamics is a pathogenic process in dementias involving tau, expanding the group of neurodegenerative diseases that involve disrupted nucleocytoplasmic transport and suggesting common mechanisms of neuronal dysfunctional in these heterogeneous conditions.

Increased Phosphorylation and Altered Cellular Localization of Tau in FTD-MAPT Neurons

To study the effects on neuronal cell biology of FTD-MAPT mutations, we generated excitatory cortical neurons from induced pluripotent stem cells (iPSCs) derived from individuals with different autosomal-dominant mutations in MAPT that are causal for early-onset FTD (Figures 1 and S1). We studied two different types of mutations: the MAPT IVS10+16 autosomal-dominant mutation, which increases inclusion of exon 10, encoding the second microtubule-binding repeat and thus altering the ratio of three (3R) and four (4R) tau isoforms, and the autosomal-dominant MAPT P301L missense mutation that produces an aggregation-prone form of tau (Figures 1 and S1). The cortical identity of the neurons generated and the reproducibility of the culture compositions among genotypes was confirmed by assessing the expression of a set of classifier genes that define different neuronal cell types (Figure S1).

Total tau content was similar in neurons of each genotype, collectively referred to here as FTD-MAPT neurons (Figure 1A). Notably, tau phosphorylation was increased in FTD-MAPT neurons compared with controls (Figure 1A), including at Ser404 and Ser202/Thr205 (AT8), epitopes typically hyperphosphorylated in tau-mediated dementias. As both mutations are dependent on expression of exon 10 of MAPT, we confirmed translation of exon 10 in neurons generated from all iPSC lines by western blotting and mass spectrometry (Figures 1B, 1C, and S1). No significant difference in insoluble, aggregated tau was detected by sarkosyl extraction between neurons of each genotype (Figure S1).

Mislocalization of tau from axons to neuronal cell bodies and dendrites is an early event in FTD in vivo. As expected, control neurons showed a predominantly axonal distribution of tau, with tau largely absent from MAP2-positive neuronal cell bodies and dendrites (Figure 1D). In contrast, tau was commonly present in MAP2-positive cell bodies and dendrites in both MAPT IVS10+16 and P301L neurons (Figures 1D and 1E). Furthermore, tau within cell bodies and dendrites of FTD-MAPT neurons was hyperphosphorylated, as detected by AT8-immunoreactivity (phospho-S202/T205) (Figure 1D).

Microtubules Invade the Nucleus in FTD-MAPT Neurons

Given the mislocalization of tau to the cell bodies of FTD-MAPT neurons, we studied neuronal microtubule dynamics in control and FTD-MAPT neurons (Figures 2 and S2). Actively extending microtubules were live-imaged in iPSC-derived neurons of each genotype by expression of GFP-tagged EB3 (Figure 2; Videos S1 and S2), the microtubule plus-end binding protein (+TIP). Total microtubule movements were not different between non-demented control and FTD-MAPT neurons, with similar rates of extensions and retractions measured among the various genotypes (Table S1).

However, microtubule dynamics were qualitatively different in the cell bodies of control neurons compared with FTD-MAPT neurons. Non-demented control neurons typically had many actively growing microtubules within the cell body that extended around a smooth, oval nucleus (Figures 2A and 2B; Video S1). In contrast, many FTD-MAPT neurons had microtubules with plus ends projecting into the nucleus (15 of 26 FTD-MAPT neurons) (Figure 2B), an event that was infrequently detected in both groups of control neurons (2 of 19) (Figure 2B). Notably, those microtubules that abnormally projected into the nucleus in FTD-MAPT neurons frequently originated from a pronounced focus that resembled a microtubule organizing center (Figure 2A; Video S1). These pronounced foci were not detected in either of the control neuronal lines. We confirmed that the EB3+ microtubules that project into the neuronal nucleus are dynamically growing microtubules, as the mobility of EB3+ comets was greatly reduced following acute microtubule depolymerization (with nocodazole) (Figures S2Band S2C; Video S2).

Microtubules Deform the Nuclear Envelope in FTD-MAPT Neurons

Microtubules couple to the nuclear membrane through the LINC complex. This physical association results in transmission of mechanical forces that influence nuclear shape and integrity, affecting the function of the nuclear envelope. Given the abnormal projection of microtubules into the nucleus in FTD-MAPT neurons, we studied the shape of the nuclear envelope in iPSC-derived neurons. Marked differences were present in nuclear shape between non-demented controls and FTD-MAPT neurons, as demonstrated by large folds, or invaginations, of the laminB1-positive inner nuclear lamina within the nucleus (Figure 3). The neuronal identity of invaginated cells was confirmed by the co-staining with the cortical deep layer transcription factor CTIP2 and the pan-neuronal protein β3-tubulin (Figure 3).

Quantification of the proportions of neurons with deformation of the nuclear membrane, as defined by the presence of laminB1-positive regions within the nucleus, (Figures 3B and S3), demonstrated that deep nuclear invaginations were present in approximately 25% of MAPT P301L and 40% of MAPT IVS10+16 neurons, compared with fewer than 10% of control neurons (Figure 3B). To confirm that microtubules actively deformed the nucleus in FTD-MAPT neurons, we acutely depolymerized microtubule with the small molecule nocodazole. This significantly reduced the proportion of neurons with nuclear invaginations and restored round nuclear morphology (Figures 3C and 3D). We conclude that the pronounced deformations of the neuronal nuclear membrane in FTD-MAPT neurons are actively mediated by microtubules.

Super-resolution Imaging Demonstrates Close Apposition of Tau and Tubulin within Nuclear Lamina Invaginations

To further study the spatial relationships between tau, microtubules, and the nuclear envelope, we conducted a detailed analysis of the neuronal nucleus in iPSC-derived neurons using three-dimensional (3D) stimulated emission depletion (STED) super-resolution imaging. Three-dimensional STED imaging demonstrated that invaginations of the nuclear lamina present in FTD-MAPT neurons commonly extended deeply into the nucleus, in some cases traversing the entire length of the nucleus, forming pronounced folds (Figure 4A). In comparison, nuclei from non-demented controls had a regular, smooth morphology, with few examples of nuclear lamina invaginations (Figure 4A).

As observed by confocal microscopy, tau protein was found to be abundant in the cell bodies of FTD-MAPT neurons by STED imaging and in those neurons was closely apposed to the outer nuclear membrane (Figure 4B). Both tau protein and neuronal tubulin were found within nuclear lamina invaginations in FTD-MAPT neurons (Figure 4B). STED imaging demonstrated that tau within nuclear membrane invaginations is within hundreds of nanometers of the nuclear lamina (Figure 4C). Given that laminB1 filaments line the inner surface of the nuclear envelope, which is typically of the order of 15–60 nm in width, we conclude that tau is in close proximity to proteins in the outer membrane of the nuclear envelope in FTD-MAPT neurons.

Tau-Containing Nuclear Lamina Invaginations in Neurons of the Post-mortem FTD-MAPT Cerebral Cortex

Having identified nuclear lamina defects in iPSC-derived FTD-MAPT neurons, we asked whether alterations of the nuclear lamina are also a feature of FTD-MAPT in vivo. To do so, we studied the incidence of invaginations of the nuclear lamina in the frontal and temporal cortex from two separate cohorts from independent brain banks, both containing individuals diagnosed with FTD due to MAPT IVS10+16 mutations and compared with age-matched non-demented controls. These cohorts were analyzed separately using different methods for detecting laminB1. We quantified the fraction of all nuclei with invaginations within each brain region (Figure 5). Similar results were obtained in both cohorts: the frequency of nuclear lamina invaginations was higher in the deep cortical layers in post-mortem cerebral cortices from individuals with FTD due to the MAPT IVS10+16 mutation, compared with non-demented control individuals (Figures 5 and S4). This was the case in both frontal and temporal cortex (Figures 5B, 5E, and 5F).

Data from iPSC-derived FTD-MAPT neurons suggested that laminB1-positive nuclear invaginations would be associated with the presence of phosphorylated tau within the neuronal cell body. Consistent with this, we found that the nuclear lamina was grossly disrupted in neurons that had high levels of hyperphosphorylated (AT8+) tau and neurofibrillary tangles in the post-mortem FTD-MAPT IVS10+16 cerebral cortex (Figures 5C and S4B), and those neurons frequently contained pronounced nuclear lamina invaginations (Figures 5C and S4B). Furthermore, nuclear lamina invaginations in such neurons also commonly contained AT8-positive hyperphosphorylated tau (Figure 5C).

Disrupted Nucleocytoplasmic Transport in FTD-MAPT Neurons

Abnormalities of the nuclear lamina are also found in aging diseases, such as Hutchinson-Gilford progeria syndrome. Nuclear membrane distortion in response to mechanical forces leads to deleterious effects on many aspects of nuclear function, disrupting nucleocytoplasmic transport. We confirmed that the nuclear lamina/membrane invaginations present in iPSC-derived FTD-MAPT neurons also contained nuclear pores within these membrane folds, with nuclear pores (labeled by NUP98) co-localizing with laminB1-positive invaginations (Figure S5A).

To assess whether alterations in the nuclear membrane in FTD-MAPT neurons result in defects in nucleocytoplasmic transport, we expressed NES:GFP and NLS:RFP from a single construct in iPSC-derived neurons. This assay enables measurement of the integrity of both nuclear localization and accumulation and cytoplasmic retention and nuclear exclusion within individual neurons (Figures 6A and S5B). Control iPSC-derived neurons had discrete cellular distributions of each protein, with prominent nuclear RFP and cytosolic GFP (Figure 6B). In contrast, localization of NLS:RFP was altered in FTD-MAPT neurons such that there was a marked decrease in the nuclear/cytoplasmic RFP ratio (Figure 6C). Conversely, nuclear exclusion of NES:GFP was reduced in FTD-MAPT neurons, with an increase of GFP within the nucleus (Figure 6C). Together, these data demonstrate defects in the selective permeability of the nuclear envelope in FTD-MAPT neurons, indicating a general failure of nucleocytoplasmic transport within FTD-MAPT neurons.

Defective nucleocytoplasmic transport may be a cumulative phenomenon due to protracted nuclear membrane damage, or an acute process due to microtubule-mediated nuclear membrane deformation. To distinguish between these mechanisms, we acutely depolymerized microtubules with nocodazole in control and FTD-MAPT neurons and quantified nucleocytoplasmic transport using the NES:GFP/NLS:RFP assay. This treatment corrected the distribution of both NES:GFP and NLS:RFP in FTD-MAPT neurons, restoring the nucleocytoplasmic ratios to the level of healthy control neuron (Figure 6D). We conclude that defective nucleocytoplasmic transport in FTD-MAPT neurons is an ongoing process due to microtubule-mediated deformation of the nuclear membrane.

Discussion

The cellular and molecular biology of the pathogenesis of FTD due to MAPT mutations is not well understood. Currently, it is thought that MAPT mutations all lead to tau protein aggregation and that protein aggregation is the primary driver of neurodegeneration. However, protein aggregation may represent only the late stage of the disease, and the processes preceding and leading to neurofibrillary tangle formation and cellular dysfunction remain to be elucidated. Here we report the use of human stem cell systems to study the effects of those mutations on neuronal cell biology, finding that tau-mediated dementias are accompanied by defective neuronal nucleocytoplasmic transport.

Focusing on two different types of MAPT mutations causal for FTD, we have found that both IVS10+16 and P301L mutations lead to marked defects in nucleocytoplasmic transport in human neurons. We find that both missense and splicing mutations in MAPT alter tau protein localization and phosphorylation within iPSC-derived neurons within 4 months in cell culture, recapitulating a well-described aspect of early FTD pathology in vivo, without detectable tau aggregation. Mislocalization of tau in the cell bodies of FTD-MAPT neurons in culture leads to marked changes in microtubule dynamics, causing deformation of the nuclear membrane both in cell culture and in the human FTD-MAPT cortex in vivo. Disruption of the nuclear lamina is commonly associated with dysfunction of the nuclear envelope, and we find marked disruption of nucleocytoplasmic transport in FTD-MAPT neurons. Disrupted nucleocytoplasmic transport is due to ongoing microtubule-mediated nuclear membrane deformation, as it is corrected by acute microtubule depolymerization. Together, these data indicate that perturbation of the function of the nuclear membrane and disruption of nucleocytoplasmic transport is an important pathological process in FTD due to MAPT mutations.

An early event in FTD is the mislocalization of tau from axons to cell bodies and dendrites, and this key stage in disease progression is also an early event in iPSC-derived models of FTD-MAPT. In vivo, mislocalization of tau is typically associated with tau hyperphosphorylation. We find this also occurs in iPSC-derived FTD-MAPT neurons, where we detected increased tau phosphorylation at serine 202/threonine 205 (the AT8 epitope) and also at serine 404. The sequence in which mislocalization and hyperphosphorylation take place in FTD in vivo, and in iPSC-derived FTD-MAPT neurons in culture, is not currently clear, nor are the mechanisms by which these processes occur. The appearance of tau within cell bodies and dendrites indicates a breakdown of the cellular polarity mechanisms that maintain the axonal enrichment of tau protein and its exclusion from the somatodendritic compartment, mechanisms that are poorly understood.

The two heterozygous, dominant MAPT mutations studied here have different effects on tau protein in neurons. The MAPT P301L missense mutation, like many missense mutations in the microtubule-binding region domain of MAPT, increases the tendency of tau to aggregate in cell-free assays and in transgenic mouse models. In contrast, the IVS10+16 mutation is not a coding mutation but rather is an intronic single base change that favors the inclusion of exon 10 in the MAPT mRNA, increasing the amount of tau containing four microtubule-binding repeats (4R), relative to the three-repeat (3R) form. However, despite these differences, the changes in the forms of tau in both MAPT P301L and IVS10+16 neurons both lead to mislocalization and increased phosphorylation of tau. This finding suggests that either the presence of a pool of P301L tau, or a shift in the 3R/4R tau ratio, alter a common pathway that regulates tau distribution within neurons, tau phosphorylation, or both.

In both MAPT IVS 10+16 and P301L mutant neurons, the appearance of tau in cell bodies is accompanied by marked qualitative changes in neuronal microtubule dynamics. Microtubules in FTD-MAPT neurons actively deform the nuclear envelope, which we find can be reversed by depolymerization of microtubules. Tau has multiple roles in stabilizing microtubules, and microtubules are coupled to the nuclear membrane through the LINC complex. Therefore, it is likely that the overall effect of the presence of tau in the cell body is to promote microtubule stability, leading to increased pushing forces on the nuclear membrane and the formation of invaginations in the nuclear membrane. As tau has recently also been found to promote microtubule nucleation when undergoing phase transitions at high concentration, accumulation of tau in the cell body may also lead to increased pushing forces on the nucleus by facilitating microtubule nucleation.

Alterations in nuclear shape and nuclear membrane function are a common feature of cellular aging, including in the nervous system, and are associated with multiple deleterious changes in nuclear biology, including chromatin changes and disrupted nucleocytoplasmic transport. Drosophila models of FTD, with neuronal expression of human MAPT R406W, have nuclear shape abnormalities and chromatin changes. Recently, nuclear membrane disruption has been reported in a MAPT P301L transgenic mouse model of FTD. Perturbations of the nuclear lamina have been described in the post-mortem AD brain, including the juxtaposition of neurofibrillary tangles of tau with the nuclear membrane. We also find here an increase in nuclear invaginations in neurons of the human post-mortem MAPT IVS10+16 cortex, and the presence of hyperphosphorylated tau within nuclear invaginations in tangle-bearing neurons. Together, these different studies are consistent with a pathological effect of tau within the neuronal cell body in FTD and AD, whereby the presence of tau alters microtubule biology, resulting in pronounced abnormalities of the neuronal nucleus and defective nucleocytoplasmic transport. Recent findings have shown a direct interaction of aggregated tau with the nuclear pore complex, suggesting that the microtubule disruption of nuclear pore function reported here may be mediated by tau protein at the nuclear membrane.

Microtubule deformation of the nucleus is a phenotype also seen in classic laminopathies such as the accelerated aging disorder Hutchinson-Gilford progeria syndrome (HGPS), in which the primary defect is due to mutant lamin A/C protein. In that case, microtubules also contribute to nuclear deformations, leading to defects in nucleocytoplasmic transport. Changes in nuclear envelope function in other neurodegenerative diseases, including ALS-FTD due to repeat expansions in C9orf72, Huntington’s disease, and AD, have recently been reported.

Our finding here of disruption of the neuronal nuclear membrane as a consequence of MAPT mutations in FTD extends this pathogenic mechanism to dementias in which protein aggregation has been thought to be the primary driver of neurodegeneration. These data suggest that dysfunction of the nuclear membrane may be a common pathogenic process in diverse neurodegenerative diseases, which could be targeted therapeutically with agents that regulate microtubule functions, nucleocytoplasmic transport, and/or associated processes.

Contact for Reagent and Resource Sharing

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rick Livesey (r.livesey@ucl.ac.uk).

Human iPSC lines

MAPT IVS10+16-A and MAPT IVS10+16-B mutant iPSCs were as reported in. MAPT P301L was generated from Janssen Pharmaceutica by TALEN editing the line MAPT P301-isogenic, under the IMI STEMBANCC project agreement ICD 483960. The non-demented control line was previously reported. iPSC cells were growth and expanded in feeder-free conditions using Essential 8 Medium (Thermo Fisher Scientific), at 37°C with 5% CO2. Essential 8 Medium was replaced daily.

Human post-mortem brain sections

Human brain sections were obtained from the Queen’s Square Brain Bank, Institute of Neurology, University College London (cohort one) and from the London Neurodegenerative Diseases Brain Bank and Brains for Dementia Research (cohort two). For cohort one, control brains included one male (age 71) and one female (age 56). FTD-MAPT IVS10+16 brains were from two males (age 52 and 66). For cohort two, control brains were from five males (age 63-77) and one female (age 43). FTD-MAPT IVS10+16 brains were from four males (age 48-71) and two females (age 58 and 63). The use of human post-mortem tissues for this study has been approved with Research Ethics Committee reference ID 08/H0718/54+5 for cohort one and reference ID 08/MRE09/38+5 for cohort two.

Generation of iPSC-derived cortical neurons and drug treatments

Differentiation of iPSCs to cortical neurons was carried out as described, with minor modifications. Briefly, dissociated iPSCs were plated on Geltrex (Thermo Fisher Scientific)-coated plates to reach full confluence. Neural induction was initiated the next day (Day 0) by changing the culture medium to a 1:1 mixture of DMEM/N-2 (DMEM/F-12 GlutaMAX; 1 × N-2; 5 μg ml−1 insulin; 1 mM L-glutamine; 100 μm non-essential amino acids; 100 μM β-mercaptoethanol; 50 U ml−1 penicillin and 50 mg ml−1 streptomycin) and Neurobasal/B-27 (Neurobasal; 1 × B-27; 200 mM L-glutamine; 50 U ml−1 penicillin and 50 mg ml−1 streptomycin) media (hereafter referred as N2B27) supplemented with 1 μM dorsomorphin and 10 μM SB431542 to inhibit TGFβ signaling and support neuronal differentiation and neurogenesis, media was replaced every 24 hours. At day 12 neuroepithelial sheet was harvested and dissociated using the enzyme Dispase and replated on laminin-coated plates. The day after, media was replaced with N2B27 containing 20 ng/mL FGF2. N2B27+FGF2 was added freshly daily for 4 days to promote the maturation of neural rosettes. After 4 days FGF2 was withdrawn and neural rosettes were maintained in N2B27 refreshing medium every other day. At day 30 neural rosettes were dissociated using Accutase and neural progenitor cells were plated on laminin-coated plates at 150,000 cells/mm2. Plated neurons were maintained for up to 120 days with a medium change every other day. To establish identity and quality of cortical neuronal inductions, gene expression profiling was performed on a custom gene expression panel. RNA was isolated from induced cortical neurons using TRIzol (Thermo Fisher Scientific), according to the manufacturer’s instructions. Expression levels of mRNAs enriched in deep and upper layer cortical neurons were assessed using a nanoString (nanoString Technologies) gene expression panel of approximately 250 genes. After subtracting the maximum negative control probe counts, gene counts were normalized using the geometric mean of 6 positive control probes and of 7 housekeeping genes (CLTC, GAPDH, GUSB, PPIA, RPLP1, RPS15A, RPS9). For nocodazole (Tocris) treatment, neurons were grown for 120 days in vitro (DIV) and compound was added at 33 μM for 2 hours before imaging. DMSO was used as vehicle.

Protein extraction and western blot analysis

Total cell protein was extracted using RIPA buffer (Sigma) supplemented with protease inhibitors (Sigma) and Halt phosphatase inhibitors (Thermo Fisher Scientific). Protein quantification was performed using Precision Red Advanced Protein Assay buffer (Cytoskeleton, Inc.). For each sample, 30 μg of protein were mixed with 1X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) + 1 μM Dithiothreitol. Samples were heated at 100°C for 10 minutes and loaded on NuPAGE 4%–12% Bis-Tris gel (Thermo Fisher Scientific). Afterward, proteins were transferred on PVDF membrane (Millipore) for 1 h at 100 V. Membranes were blocked for another 60 min in 5% BSA in PBST (PBS containing 0.05% Tween 20). All primary antibodies were incubated overnight in 5% milk in PBST at 4°C. Next day, membranes were incubated for at least 1 h in secondary antibody and washed gently in PBST buffer for further 30-60 min. Immunoblots were detected using LI-COR Odyssey CLx Infrared Imaging System and processed with the Image Studio Software (LI-COR).

Sarkosyl extraction

iPSC-derived neurons (120 DIV) were homogenized in Tris-NaCl buffer (25 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM Na4P2O7, pH 7.6) supplemented with 1 mM PMSF, protease inhibitors (Sigma) and Halt phosphatase inhibitors (Thermo Fisher Scientific). Homogenate was subjected to ultracentrifugation at 150,000 g for 30 min at 4°C. The pellet was re-suspended in an equal volume of 10 mM TrisHCl, 0.8 M NaCl, 10% sucrose, pH 7.6 supplemented with 1 mM PMSF, protease inhibitors and Halt phosphatase inhibitors. The re-suspended pellet was centrifuged at 20,000 g for 30 min at 4°C, the supernatant was incubated with 1% sarkosyl (N-lauroylsarkosine sodium salt; Sigma) for 1 hour at room temperature and ultracentrifuged at 150,000 g for 30 min at 4°C. The resulting pellet (sarkosyl insoluble fraction) was resuspended in 1X NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) + 1 mM Dithiothreitol. Samples were heated at 100°C for 10 minutes and loaded on NuPAGE 4%–12% Bis-Tris gel (Thermo Fisher Scientific).

Immunoprecipitation and mass spectrometric analysis of intracellular tau

Tau was immunoprecipitated from 1 mg of total protein extracted from iPSC-derived neurons (120 DIV) using a polyclonal anti-tau antibody (Dako Cytomation). Immunoprecipitated samples were analyzed by western blot using a monoclonal tau antibody (MN1000; Thermo Fisher Scientific) or stained with colloidal blue (Thermo Fisher Scientific). Bands that corresponded to tau by western blot analysis were excised from the colloidal blue SDS-PAGE. Peptide masses of digested protein samples were determined using a Bruker ultrafleXtreme Maldi mass spectrometer in reflectron mode and ms/ms fragmentation performed in LIFT mode. Data analysis was with FlexAnalysis, BioTools and ProteinScape software (Bruker). Database searches of the combined mass fingerprint-ms/ms data were performed using Mascot (http://www.matrixscience.com).

RNA extraction and qRT-PCR analysis

Total RNA was extracted using TRIzol according to manufacturer protocol (Invitrogen). 1 μg of RNA was treated with DNase I (New England BioLabs) and 500 ng were retrotranscribed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qRT-PCR were performed in a StepOnePlus instrument (Applied Biosystems) using the SYBR Green JumpStart Taq Ready Mix (Sigma) in a final volume of 15 μl, using the following protocol: 95°C for 2 min, 40 cycles at 94°C for 15 s, 60°C for 30 s. MAPT mRNA expression was assessed relative to GAPDH and RPS9 housekeeping genes using the specific primers reported in the Key Resource Table. Results were analyzed using the ABI StepOnePlus software (Thermo Fisher Scientific).

Confocal microscopy and image analysis

For immunofluorescent labeling and imaging, cells were washed 3 times in PBS and then fixed using 4% paraformaldehyde (v/v) in PBS for 15 minutes at RT. After 3 washes in PBS, cells were permeabilised in PBS+0.3% Triton X-100 (Sigma; Tx) for 15 minutes at room temperature (RT). After 3 washes in PBS, cells were blocked using 5% donkey serum in PBS+0.3% Triton X-100 (PBS-Tx+5% DS) for 1 hr at RT. For AT8-tau immunostaining (ThermoFisher; MN1020), 5% BSA (Sigma) (w/v) in PBS+0.3% Triton X-100 (PBS-Tx+5% BSA) was used as a blocking agent. Primary antibodies were diluted in PBS-Tx+5% DS or PBS-Tx+5% BSA as indicated below and incubated overnight at 4°C. Cells were washed 3 times in PBS and incubated 1 hr in the dark at RT with secondary antibodies diluted 1:1000 in PBS-Tx+5% DS or PBS-Tx+5% BSA. After 3 washes in PBS, samples were incubated for 5 minutes at RT with DAPI diluted 1:5000 in PBS and then washed 3 additional times with PBS. Samples were mounted using ProLong Gold antifade (Thermo Fisher Scientific).

Standard confocal images were acquired with an Olympus Inverted FV1000 confocal microscope and processed using Fiji software. STED imaging was performed on a custom built, dual color, beam scanning system with gated detection optically identical to the instrument described in.

For image analysis of colocalization of tau and MAP2, Pearson’s R correlation was calculated using the Coloc2 plugin for Fiji (https://imagej.net/Coloc2). To quantify nuclear invaginations neurons were co-stained for LaminB1 and DAPI. Nuclear lamina signal was assigned as either nuclear boundary or invaginated (i.e., within the DAPI stained area defining the nucleus) using a custom plugin for the Fiji bioimage analysis software. Nuclei with a proportion of invaginated laminB1 that exceeded 0.3 were considered as invagination positive (see Figure 3B and S3 for details). At least 5 imaging fields from three independent experiments for genotype were analyzed.

Staining of human formalin-fixed paraffin embedded (FFPE) brain sections

FFPE slides were deparaffinised and rehydrated, then boiled for 20 minutes in 10 mM Tri-sodium citrate buffer, pH6 + 0.05% Tween 20, for antigen retrieval. Slides were cooled to RT before staining. 3,3′-Diaminobenzidine (DAB) staining was performed using the DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories) according to manufacturer’s instructions. After DAB staining, whole sections were imaged using an Axio Scan.Z1 microscope (Zeiss). For immunofluorescence, after antigen retrieval slides were blocked using 5% BSA in PBS+0.3% Triton X-100 (PBS-Tx+5% BSA) for 20 minutes at RT. Primary antibodies were diluted in PBS-Tx+5% BSA as indicated below and incubated O/N at 4°C in humidified chamber. Slides were washed 3 times in PBS and incubated for 30 minutes in the dark at RT with secondary antibodies diluted 1:1000 in PBS-Tx+5% BSA. After 3 washes in PBS, samples were incubated 5 minutes with DAPI diluted 1:5000 in PBS. After 3 washes in PBS, slides were incubated for 20 minutes with 0.01% Sudan Black B (Sigma) in 70% ethanol. Samples were mounted using ProLong Gold antifade (Thermo Fisher Scientific). Images were acquired through Olympus Inverted FV1000 confocal microscope and processed using the Fiji software.

For cohort one, nuclear lamina invaginations were quantified after 3,3′-Diaminobenzidine (DAB) staining of LaminB1. Nuclei were scored from 20 randomly acquired imaging fields from each individual. Nuclei were considered positive (folded) if invaginations extended into the nuclear interior for at least 3 μm. The percentage of folded respect to total nuclei was calculated for each imaging field. For cohort two, neurons were co-stained for LaminB1 and DAPI. Nuclear lamina signal was assigned as either nuclear boundary or invaginated (i.e., within the DAPI stained area defining the nucleus) using custom plugin for the Fiji bioimage analysis software. Nuclei with a proportion of invaginated laminB1 that exceeded 0.3 were considered as invagination positive (see Figure 3B and S3 for details).

Live imaging of microtubule dynamics

Neurons were grown to 100 DIV in individual μ-Dish 35 mm dishes (Ibidi) and transfected with a plasmid encoding for GFP-EB3 (gift from Michael Davidson; Addgene plasmid # 56474). 48h after transfection, neurons were subjected to live imaging using a Leica SP5 microscope equipped with a controlled environment chamber (37°C; 5% CO2). Images were acquired at resonant scanning with a 63x objective (1frame/sec). Resulting movies were analyzed using the plusTipTracker software.

Nucleocytoplasmic transport assay

Nucleocytoplasmic trafficking was analyzed by infection of 120 DIV human iPSC-derived neurons with the pLVX-EF1alpha-2xGFP:NES-IRES-2xRFP:NLS construct (Addgene plasmid #71396; ). After 6 days, neurons were fixed and immunostained for β3-tubulin and GFP. Only cells positive for neuron-specific β3-tubulin were considered. The nuclear to cytoplasmic ratios of both GFP and RFP (nucRFP:cytRFP and nucGFP:cytGFP) were calculated separately using the integrated density of ROIs drawn within and outside the nucleus (see Fig.S5 for details).

Quantification and statistical analysis

Unless otherwise specified, data are presented as mean values of the number of independently conducted experiments indicated in the legend of each figure. Error bars represent the standard error of mean (SEM). Statistical analysis was performed using the Prism6 analytical software (GraphPad). Unpaired Student’s t test was used to compare differences between two groups, assuming the data were normally distributed. One-way ANOVA followed by Tukey’s or Dunnett’s correction for multiple testing (as indicated in figure legends) was used to analyze the differences between more than two groups. ∗∗∗ p < 0.01, ∗∗p < 0.01, ∗p < 0.05.

References 60

  1. 1.

    Akhmanova A., Steinmetz M.O. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell Biol. 2008;9:309-322.

    Not in our library10.1038/nrm2369

  2. 2.

    Alonso Adel.C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 2004;279:34873-34881.

    Not in our library10.1074/jbc.m405131200

  3. 3.

    Applegate K.T., Besson S., Matov A., Bagonis M.H., Jaqaman K., Danuser G. plusTipTracker: quantitative image analysis software for the measurement of microtubule dynamics. J. Struct. Biol. 2011;176:168-184.

    Not in our library10.1016/j.jsb.2011.07.009

  4. 4.

    Ballatore C., Lee V.M.-Y., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663-672.

    Not in our library10.1038/nrn2194

  5. 5.

    Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552-1555.

    Not in our library10.1126/science.292.5521.1552

  6. 6.
  7. 7.

    Broers J.L.V., Ramaekers F.C.S., Bonne G., Yaou R.B., Hutchison C.J. Nuclear lamins: laminopathies and their role in premature ageing. Physiol. Rev. 2006;86:967-1008.

    Not in our library10.1152/physrev.00047.2005

  8. 8.

    Burke B., Stewart C.L. The nuclear lamins: flexibility in function. Nat. Rev. Mol. Cell Biol. 2013;14:13-24.

    Not in our library10.1038/nrm3488

  9. 9.
  10. 10.

    Capell B.C., Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 2006;7:940-952.

    Not in our library10.1038/nrg1906

  11. 11.

    Chang W., Worman H.J., Gundersen G.G. Accessorizing and anchoring the LINC complex for multifunctionality. J. Cell Biol. 2015;208:11-22.

    Not in our library10.1083/jcb.201409047

  12. 12.
  13. 13.

    Crisp M., Liu Q., Roux K., Rattner J.B., Shanahan C., Burke B., Stahl P.D., Hodzic D. Coupling of the nucleus and cytoplasm: role of the LINC complex. J. Cell Biol. 2006;172:41-53.

    Not in our library10.1083/jcb.200509124

  14. 14.

    D’Souza I., Poorkaj P., Hong M., Nochlin D., Lee V.M., Bird T.D., Schellenberg G.D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. U S A. 1999;96:5598-5603.

    Not in our library10.1073/pnas.96.10.5598

  15. 15.

    Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L.F. Differential regulation of dynein and kinesin motor proteins by tau. Science. 2008;319:1086-1089.

    Not in our library10.1126/science.1152993

  16. 16.

    Eftekharzadeh B., Daigle J.G., Kapinos L.E., Coyne A., Schiantarelli J., Carlomagno Y., Cook C., Miller S.J., Dujardin S., Amaral A.S. Tau protein disrupts nucleocytoplasmic transport in Alzheimer’s disease. Neuron. 2018;99:925-940.e7.

    Not in our library10.1016/j.neuron.2018.07.039

  17. 17.

    Fitzpatrick A.W.P., Falcon B., He S., Murzin A.G., Murshudov G., Garringer H.J., Crowther R.A., Ghetti B., Goedert M., Scheres S.H.W. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547:185-190.

    Not in our library10.1038/nature23002

  18. 18.

    Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.-H., Badders N., Valentine M., Miller B.L., Wong P.C. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129-133.

    Not in our library10.1038/nature14974

  19. 19.

    Frost B. Alzheimer’s disease: An acquired neurodegenerative laminopathy. Nucleus. 2016;7:275-283.

    Not in our library10.1080/19491034.2016.1183859

  20. 20.

    Frost B., Bardai F.H., Feany M.B. Lamin dysfunction mediates neurodegeneration in tauopathies. Curr. Biol. 2016;26:129-136.

    Not in our library10.1016/j.cub.2015.11.039

  21. 21.

    Fu H., Hussaini S.A., Wegmann S., Profaci C., Daniels J.D., Herman M., Emrani S., Figueroa H.Y., Hyman B.T., Davies P., Duff K.E. 3D visualization of the temporal and spatial spread of tau pathology reveals extensive sites of tau accumulation associated with neuronal loss and recognition memory deficit in aged tau transgenic mice. PLoS ONE. 2016;11:e0159463.

    Not in our library10.1371/journal.pone.0159463

  22. 22.

    Gerace L., Huber M.D. Nuclear lamina at the crossroads of the cytoplasm and nucleus. J. Struct. Biol. 2012;177:24-31.

    Not in our library10.1016/j.jsb.2011.11.007

  23. 23.

    Goedert M., Ghetti B., Spillantini M.G. Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006254.

    Not in our library10.1101/cshperspect.a006254

  24. 24.

    Götz J., Probst A., Spillantini M.G., Schäfer T., Jakes R., Bürki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995;14:1304-1313.

    Not in our library10.1002/j.1460-2075.1995.tb07116.x

  25. 25.

    Grima J.C., Daigle J.G., Arbez N., Cunningham K.C., Zhang K., Ochaba J., Geater C., Morozko E., Stocksdale J., Glatzer J.C. Mutant Huntingtin disrupts the nuclear pore complex. Neuron. 2017;94:93-107.e6.

    Not in our library10.1016/j.neuron.2017.03.023

  26. 26.

    Hernández-Vega A., Braun M., Scharrel L., Jahnel M., Wegmann S., Hyman B.T., Alberti S., Diez S., Hyman A.A. Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase. Cell Rep. 2017;20:2304-2312.

    Not in our library10.1016/j.celrep.2017.08.042

  27. 27.

    Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.-L. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067-1081.

    Not in our library10.1016/j.neuron.2010.11.030

  28. 28.

    Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702-705.

    Not in our library10.1038/31508

  29. 29.

    Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012;482:216-220.

    Not in our library10.1038/nature10821

  30. 30.

    Jovičić A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., Sun S., Herdy J.R., Bieri G. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226-1229.

    Not in our library10.1038/nn.4085

  31. 31.

    Kadavath H., Hofele R.V., Biernat J., Kumar S., Tepper K., Urlaub H., Mandelkow E., Zweckstetter M. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc. Natl. Acad. Sci. U S A. 2015;112:7501-7506.

    Not in our library10.1073/pnas.1504081112

  32. 32.

    Kelley J.B., Datta S., Snow C.J., Chatterjee M., Ni L., Spencer A., Yang C.-S., Cubeñas-Potts C., Matunis M.J., Paschal B.M. The defective nuclear lamina in Hutchinson-Gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol. Cell. Biol. 2011;31:3378-3395.

    Not in our library10.1128/mcb.05087-11

  33. 33.

    Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer’s disease. Ann. Neurol. 1987;22:639-643.

    Not in our library10.1002/ana.410220514

  34. 34.

    Larrieu D., Britton S., Demir M., Rodriguez R., Jackson S.P. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014;344:527-532.

    Not in our library10.1126/science.1252651

  35. 35.

    Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121-1159.

    Not in our library10.1146/annurev.neuro.24.1.1121

  36. 36.

    Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000;25:402-405.

    Not in our library10.1038/78078

  37. 37.

    Lim J., Yue Z. Neuronal aggregates: formation, clearance, and spreading. Dev. Cell. 2015;32:491-501.

    Not in our library10.1016/j.devcel.2015.02.002

  38. 38.

    Luo Y., Lee I.-W., Jo Y.-J., Namgoong S., Kim N.-H. Depletion of the LINC complex disrupts cytoskeleton dynamics and meiotic resumption in mouse oocytes. Sci. Rep. 2016;6:20408.

    Not in our library10.1038/srep20408

  39. 39.

    Mertens J., Paquola A.C.M., Ku M., Hatch E., Böhnke L., Ladjevardi S., McGrath S., Campbell B., Lee H., Herdy J.R. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17:705-718.

    Not in our library10.1016/j.stem.2015.09.001

  40. 40.

    Oberdoerffer P., Sinclair D.A. The role of nuclear architecture in genomic instability and ageing. Nat. Rev. Mol. Cell Biol. 2007;8:692-702.

    Not in our library10.1038/nrm2238

  41. 41.

    Rossor M.N., Fox N.C., Mummery C.J., Schott J.M., Warren J.D. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9:793-806.

    Not in our library10.1016/s1474-4422(10)70159-9

  42. 42.

    Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676-682.

    Not in our library10.1038/nmeth.2019

  43. 43.
  44. 44.

    Sheffield L.G., Miskiewicz H.B., Tannenbaum L.B., Mirra S.S. Nuclear pore complex proteins in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65:45-54.

    Not in our library10.1097/01.jnen.0000195939.40410.08

  45. 45.

    Shi Y., Kirwan P., Livesey F.J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 2012;7:1836-1846.

    Not in our library10.1038/nprot.2012.116

  46. 46.

    Shi Y., Kirwan P., Smith J., Robinson H.P.C., Livesey F.J. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 2012;15:477-486.

    Not in our library10.1038/nn.3041

  47. 47.

    Snow C.J., Dar A., Dutta A., Kehlenbach R.H., Paschal B.M. Defective nuclear import of Tpr in Progeria reflects the Ran sensitivity of large cargo transport. J. Cell Biol. 2013;201:541-557.

    Not in our library10.1083/jcb.201212117

  48. 48.

    Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609-622.

    Not in our library10.1016/s1474-4422(13)70090-5

  49. 49.
  50. 50.

    Thies E., Mandelkow E.-M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 2007;27:2896-2907.

    Not in our library10.1523/jneurosci.4674-06.2007

  51. 51.

    Trinczek B., Ebneth A., Mandelkow E.M., Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci. 1999;112:2355-2367.

    Not in our library10.1242/jcs.112.14.2355

  52. 52.

    von Bergen M., Barghorn S., Biernat J., Mandelkow E.-M., Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim. Biophys. Acta. 2005;1739:158-166.

    Not in our library10.1016/j.bbadis.2004.09.010

  53. 53.

    Wang Y., Mandelkow E. Tau in physiology and pathology. Nat. Rev. Neurosci. 2016;17:5-21.

    Not in our library10.1038/nrn.2015.1

  54. 54.

    Wang J.-Z., Xia Y.-Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. 2013;33(Suppl 1):S123-S139.

    Not in our library10.3233/jad-2012-129031

  55. 55.

    Webster M., Witkin K.L., Cohen-Fix O. Sizing up the nucleus: nuclear shape, size and nuclear-envelope assembly. J. Cell Sci. 2009;122:1477-1486.

    Not in our library10.1242/jcs.037333

  56. 56.

    Witman G.B., Cleveland D.W., Weingarten M.D., Kirschner M.W. Tubulin requires tau for growth onto microtubule initiating sites. Proc. Natl. Acad. Sci. U S A. 1976;73:4070-4074.

    Not in our library10.1073/pnas.73.11.4070

  57. 57.

    Zempel H., Mandelkow E.-M. Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer disease and hereditary spastic paraplegia. Mol. Neurodegener. 2015;10:68.

    Not in our library10.1186/s13024-015-0064-1

  58. 58.

    Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56-61.

    Not in our library10.1038/nature14973

  59. 59.

    Zhang Y.-J., Gendron T.F., Grima J.C., Sasaguri H., Jansen-West K., Xu Y.-F., Katzman R.B., Gass J., Murray M.E., Shinohara M. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 2016;19:668-677.

    Not in our library10.1038/nn.4272

  60. 60.

    Zhang K., Daigle J.G., Cunningham K.M., Coyne A.N., Ruan K., Grima J.C., Bowen K.E., Wadhwa H., Yang P., Rigo F. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958-971.e17.

    Not in our library10.1016/j.cell.2018.03.025

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.